Creative Medical Technology Holdings Inc (CELZ) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Creative Medical Technology Holdings Inc (CELZ) has a cash flow conversion efficiency ratio of -0.209x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.17 Million) by net assets ($5.59 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Creative Medical Technology Holdings Inc - Cash Flow Conversion Efficiency Trend (2006–2024)
This chart illustrates how Creative Medical Technology Holdings Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does Creative Medical Technology Holdings Inc carry for a breakdown of total debt and financial obligations.
Creative Medical Technology Holdings Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Creative Medical Technology Holdings Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Box Pak (Malaysia) Bhd
KLSE:6297
|
-0.201x |
|
Processa Pharmaceuticals Inc
NASDAQ:PCSA
|
-0.520x |
|
Kerlink SAS
PA:ALKLK
|
0.163x |
|
Watta Holding Bhd
KLSE:7226
|
-0.034x |
|
Openn Negotiation Ltd
AU:OPN
|
0.905x |
|
SMIS Corporation Bhd
KLSE:7132
|
0.026x |
|
CMX GOLD+SILVER CORP.
F:6GS
|
N/A |
|
Purple Biotech
NASDAQ:PPBT
|
-0.031x |
Annual Cash Flow Conversion Efficiency for Creative Medical Technology Holdings Inc (2006–2024)
The table below shows the annual cash flow conversion efficiency of Creative Medical Technology Holdings Inc from 2006 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Creative Medical Technology Holdings Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $6.34 Million | $-5.30 Million | -0.836x | -7.71% |
| 2023-12-31 | $10.34 Million | $-8.03 Million | -0.776x | -57.92% |
| 2022-12-31 | $15.86 Million | $-7.80 Million | -0.491x | -126.63% |
| 2021-12-31 | $10.22 Million | $-2.22 Million | -0.217x | -2086.29% |
| 2020-12-31 | $-39.80 Million | $-434.56K | 0.011x | -92.74% |
| 2019-12-31 | $-8.07 Million | $-1.21 Million | 0.150x | -42.95% |
| 2018-12-31 | $-3.99 Million | $-1.05 Million | 0.263x | -33.79% |
| 2017-12-31 | $-2.24 Million | $-889.62K | 0.398x | -85.90% |
| 2016-12-31 | $-157.79K | $-445.23K | 2.822x | +3443.05% |
| 2015-12-31 | $-183.80K | $-14.64K | 0.080x | -29.63% |
| 2014-12-31 | $-153.04K | $-17.32K | 0.113x | -38.23% |
| 2013-12-31 | $-125.03K | $-22.91K | 0.183x | +6.76% |
| 2012-12-31 | $-97.75K | $-16.77K | 0.172x | -11.29% |
| 2011-12-31 | $-72.16K | $-13.96K | 0.193x | -31.88% |
| 2010-12-31 | $-48.11K | $-13.66K | 0.284x | -71.50% |
| 2009-12-31 | $-30.85K | $-30.74K | 0.996x | +101.32% |
| 2008-12-31 | $757.00 | $-57.16K | -75.514x | -15375.15% |
| 2007-12-31 | $26.35K | $-12.86K | -0.488x | -995.05% |
| 2006-12-31 | $20.89K | $1.14K | 0.055x | -- |
About Creative Medical Technology Holdings Inc
Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness. It develops AlloStem (CELZ-201-DD… Read more